Note 11 - Related Party Transactions (Details Textual)				1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 01, 2022 CAD ($)	Aug. 01, 2020 USD ($) shares	Oct. 01, 2017 CAD ($)	Jan. 31, 2017 CAD ($)	Mar. 31, 2022 CAD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 USD ($)	Jun. 30, 2022 USD ($)	Dec. 14, 2017	Dec. 02, 2017
Notes Receivable, Related Parties, Current						$ 0			$ 0
Accounts Payable, Related Parties, Current						101,422			75,561
Operating Lease, Liability, Total						310,671	$ 164,997
Operating Lease, Expense						$ 46,000	35,000
Operating Lease, Weighted Average Discount Rate, Percent						6.76%
Operating Lease, Weighted Average Remaining Lease Term (Year)						4 years 4 months 24 days
Operating Lease, Right-of-Use Asset						$ 138,103			111,853
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent			$ 2,608
Operating Lease, Impairment Loss		$ 146,795
Operating Lease, Liability, Total						177,686	164,997
Operating Lease, Expense						$ 13,000	35,000
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member]
Operating Lease, Monthly Rent	$ 3,390
Lease Arrangement, 20 North Rear Road [Member]
Operating Lease, Monthly Rent				$ 4,000
Operating Lease, Liability, Total		$ 45,118
Lessee, Operating Lease, Term of Contract (Year)				5 years
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares		36,500
Stock Issued During Period, Value, Issued for Settlement of Lease Termination		$ 50,700
Operating Lease, Right-of-Use Asset		$ 48,110
Lessee, Operating Lease, Discount Rate		8.00%
Gain (Loss) on Termination of Lease		$ 53,692
Lease Arrangement, 20 North Rear Road [Member] | General and Administrative Expense [Member]
Operating Lease, Expense		$ 20,000
Minimum [Member]
Operating Lease, Monthly Rent					$ 844
Maximum [Member]
Operating Lease, Monthly Rent					$ 5,595
CEN Biotech Ukraine [Member] | XN Pharma [Member]
Ownership Percentage										49.00%
CEN Biotech Ukraine [Member]
Percentage of Related Party's Equity Interest Owned by Director										25.50%
Business Acquisition, Percentage of Voting Interests Acquired										51.00%
Emergence Global [Member]
Notes Receivable, Related Parties, Current							17,901
Joseph Byrne [Member]
Percentage of Related Party's Equity Interest Owned						5.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total						$ 1,299,328	1,179,328		$ 1,229,328
Percentage of Related Party's Equity Interest Owned by Director											51.00%
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings								$ 255,141
Notes Receivable, Related Parties								44,859
Board Members and Officers [Member] | Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction						188,718	124,800
Due to Related Parties, Total						518,918	$ 330,200
Chief Technology Officer [Member] | Payoll Expenses [Member]
Related Party, General and Administrative Expenses						94,553
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties								$ 300,000
Director, Joe Byrne [Member] | Advances Made to the Company [Member]
Accounts Payable, Related Parties, Current						8,347
The Chief Financial Officer, Alex Tarrabain [Member]
Accounting Advisory Services, Fees						13,320
The Chief Financial Officer, Alex Tarrabain [Member] | Reimbursable Expenses [Member]
Accounts Payable, Related Parties, Current						30,795
The Chief Technology Officer, Lawrence Lehoux [Member] | Reimbursable Expenses [Member]
Accounts Payable, Related Parties, Current						$ 48,960